To investigate the feasibility of deep learning-assisted rapid silent PET/MR in pediatric applications.
Eligibility
Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
1. Children who have clinical symptoms and are suspected of having malignant tumors after being evaluated by clinical pediatricians and require 18F-FDG PET/MR examination to further clarify their conditions.
2. Signed and dated informed consent form
3. Commit to complying with the research procedures and cooperate in the implementation of the entire research process.
4. No gender restriction, aged between 0 and 18 years old.
Exclusion Criteria:
1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
2. Patients with severe claustrophobia，epileptic seizures, respiratory distress who cannot lie down, and patients with mental anomalies who are unable to cooperate.
3. Patients with metal implants such as pacemakers, artificial metal heart valves, and neurostimulators in their bodies.
4. Non-compliant person.
Primary outcome measure(s)
Lesion detection rate — 1 year Routine laboratory or imaging tests or pathology are performed based on clinical needs to assess the accuracy, sensitivity and specificity of rapid silent 18F-FDG PET/MR for lesion detection.
Completion of PET/MR examinations — 1 year Upon completion of the examination, record the rate of completion
Sedation during PET/MR examinations — 1 year Upon completion of the examination, record the rate of sedation and rate of secondary sedation
Qualitative image quality — 1 year Two experienced nuclear medicine physicians evaluated the overall quality of the images using a Likert 5-point scale for both the new imaging PET/MR protocol and the traditional imaging protocol.
Trial sites (1)
Facility
City
Region
Status
China, Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.